In CRC cells, the miR-506 has been shown to counteract resistance to the chemotherapy drug, oxaliplatin, by targeting the MDR1/P-gp drug efflux pump, which is responsible for drug efflux from the cancer cells, and concurrently inhibiting the Wnt/β-catenin pathway [157]. Here, PGP is linked to cancer.